CAS: 87638-04-8; 2-((((Z)-1-(2-Aminothiazol-4-yl)-2-(((2S,3S)-2-((Carbamoyloxy)Methyl)-4-Oxo-1-Sulfoazetidin-3-yl)Amino)-2-Oxoethylidene)Amino)Oxy)Acetic Acid
该化合物是属于乙型林丹化合物类别的合成抗生素,特别是单体,其主要特征是能够抑制细菌细胞壁合成,使其对一系列克格拉姆阴性细菌有效.卡鲁蒙姆对某些乙型乳性瘤表现出了稳定性,这些细菌是细菌生产的酶,可以使许多其他抗生菌停止活动.这一特征增强了其治疗潜力,特别是在治疗抗药菌株感染方面.该化合物通常通过注射进行,并研究其药理基因学,包括吸收,分布,代谢和排泄.其安全性特征和副作用与其他乙型阴性细胞类似,尽管个别反应可能有所不同.卡罗莫南在临床环境中的功效和安全一直是研究的主题,特别是在多药抗感染的情况下.总体而言,它的独特性质使它成为抗生酶库中的宝贵选择,特别是治疗替代品有限的病人.
- 英文名称2-((((Z)-1-(2-Aminothiazol-4-yl)-2-(((2S,3S)-2-((Carbamoyloxy)Methyl)-4-Oxo-1-Sulfoazetidin-3-yl)Amino)-2-Oxoethylidene)Amino)Oxy)Acetic Acid
- 中文名称卡芦莫南
- IUPAC名称2-((((Z)-1-(2-aminothiazol-4-yl)-2-(((2S,3S)-2-((carbamoyloxy)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)acetic acid
- 其它别名Carumonam; Acetic Acid, [[(Z)-[2-[[(2S,3S)-2-[[(Aminocarbonyl)Oxy]Methyl]-4-Oxo-1-Sulfo-3-Azetidinyl]Amino]-1-(2-Amino-4-Thiazolyl)-2-Oxoethylidene]Amino]Oxy]-; Acetic Acid, [[[2-[[2-[[(Aminocarbonyl)Oxy]Methyl]-4-Oxo-1-Sulfo-3-Azetidinyl]Amino]-1-(2-Amino-4-Thiazolyl)-2-Oxoethylidene]Amino]Oxy]-, [2S-[2α,3α(Z)]]-; (2S)-2α-(Carbamoyloxymethyl)-3α-[[(Z)-(2-Amino-4-Thiazolyl)[(Carboxymethoxy)Imino]Acetyl]Amino]-4-Oxoazetidine-1-Sulfonic Acid; [[[(Z)-2-[[(2S)-2α-[[(Aminocarbonyl)Oxy]Methyl]-4-Oxo-1-Sulfoazetidin-3α-Yl]Amino]-1-(2-Aminothiazol-4-yl)-2-Oxoethylidene]Amino]Oxy]Acetic Acid
- CAS编号87638-04-8
- MFCD编号:MFCD00871292
- FDA UNII编号:486890PI06
- 分子式:C12H14N6O10S2分子量:466.41
- 产品CID: 1884526
- 产品分类原料药 → 抗生素类药物 → β→内酰胺酶抑制剂
物理性质
- 闪点 °C
- 密度2.1±0.1 g/cm3
- PH:D26 -45° (c = 1 in DMSO)
- pKa:-0.43±0.60(预测)
- PSA:290.52
- LogP:-2.26
- 折射率1.820
- 外观形态固体-粉末
- 储存条件Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
- 产品应用该化合物用作治疗易感染性细菌(包括败血性,慢性呼吸道感染,霍乱,围膜炎,慢性支气炎,长期支气管炎和细胞炎)引起的感染.它特别表现为肺炎,麻风病,血道感染和血囊炎感染,内源感染,骨骼和联合感染,皮肤和软组织感染,尿道感染以及乳腺感染,淋病感染和性呼吸道病原体感染,以及由易性病性感染和热性感染,性感染及性感染等生物引起的血病等疾病.
MSDS等安全信息
上下游产品
(3S,4S)-3-amino-4-[(carbamoyloxy)methyl]-2-oxo-azetidine-1-sulfonic acid合成工艺路线路线简述
📜(3S,4S)-3-Amino-4-Carbamoyloxymethyl-2-Azetidinone-1-Sulfonic Acid 反应生成 卡芦莫南
参考文献:Synthesis Of Carumonam (Ama-1080) And A Related Compound Starting From (2R,3R)-Epoxysuccinic Acid.
标题:Synthesis Of Carumonam (Ama-1080) And A Related Compound Starting From (2R,3R)-Epoxysuccinic Acid.
摘要:在对磺胺氟噻嗪进行化学改造的过程中,合成了几种4-氨甲酰-2-氮杂环丁酮-1-磺酸衍生物,旨在提高其抗菌活性.在这些化合物中,(3S,4S)-3-[2-(2-氨噻唑-4-基)-(Z)-2-(1-羧基-1-甲基乙氧亚胺)乙酰氨基]-4-氨甲酰-2-氮杂环丁酮-1-磺酸(2)被发现对抗革兰氏阴性细菌具有强大的抗菌活性,结果与卡鲁莫南(1,Ama-1080; Ro 17-2301)相当.基于(2R,3R)-环氧琥珀酸(5)这一易于获取的发酵产物,开发了高效的合成路径,以大规模制备1和2.
DOI:10.1248/cpb.33.3798
海关参考信息
- 2905121000-正丙醇
2905130000-正丁醇
2905310000-1,2-乙二醇
2912110000-甲醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-4502994-A
优先权日:1982-12-09
标题 :Enantiomeric synthesis of 3-amino-4-carbamoyloxymethyl-2-azetidonone-1-sulfate
发明人：WEI CHUNG-CHEN; WEIGELE MANFRED
权利人:HOFFMANN LA ROCHE
摘要:A novel enantiomeric synthesis from ascorbic acid of (3S,4S)-3-amino-4-carbamoyloxymethyl-2-azetidinone-1-sulfate, an intermediate for an antibiotic compound.
专利号:US-2009111737-A1
优先权日:1999-05-24
标题:Novel antibacterial agents
发明人：CHRISTENSEN BURTON G; MORAN EDMUND J; GRIFFIN JOHN H; JUDICE J KEVIN; MU YONGQI; PACE JOHN L; MAMMEN MATHAI; AGGEN JAMES
权利人:CHRISTENSEN BURTON G; MORAN EDMUND J; GRIFFIN JOHN H; JUDICE J KEVIN; MU YONGQI; PACE JOHN L; MAMMEN MATHAI; AGGEN JAMES
摘要:This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands in their monovalent (i.e., unlinked) state have the ability to bind to a an enzyme involved in cell wall biosynthesis and metabolism, a precursor used in the synthesis of the bacterial cell wall and/or the bacterial cell surface thereby interfere with the synthesis and/or metabolism of the cell wall. In particular the multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands hasn a ligand domain capable of binding to penicillin binding proteins, a transpeptidase enzyme, a substrate of a transpeptidase enzyme, a beta-lactamase enzyme, pencillinase enzyme, cephalosporinase enzyme, a transglycoslase enzyme, or a transglycosylase enzyme substrate; Preferably, the ligands are selected from the beta lactam or glycopeptide class of antibacterial agents.
专利号:US-2025002508-A1
优先权日:2020-05-05
标题 :Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
发明人：HECKER SCOTT J; BOYER SERGE HENRI; BIO MATTHEW M; FANG YUANQING; GONZALES DE CASTRO ANGELA; LEFORT LAURENT; ZHU ZUOLIN; LINDER THOMAS
权利人:QPEX BIOPHARMA INC
摘要:Disclosed herein are antimicrobial compounds, polymorphic forms, compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-lactamase inhibitors (BLIs).
专利号:ES-2338657-T3
优先权日:2003-04-18
标 题 :SYNTHESIS OF 2-HYDROXI-N, N-DIMETHYL-3 - ((2 - ((1 (R) - (5-METHYL-2-FURANIL) PROPIL) AMINO) -3,4-DIOXO-1-CICLOBUTEN-1 -IL) AMINO) BENZAMIDA.
专利号:US-2016326157-A1
优先权日:2014-01-06
标 题:Monobactams and methods of their synthesis and use
发明人：MYERS ANDREW G; Seiple lan Bass; SUSSMAN ROBIN JUDITH
权利人:HARVARD COLLEGE
摘要:Described herein are monobactam antibiotics of Formula (I), (I′), (II), and (II′), along with methods and intermediates for preparing these compounds. Pharmaceutical compositions and methods of treating infectious diseases using the monobactams are also provided.
专利号:US-9149445-B2
优先权日:2009-07-27
标 题:Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections
发明人：LIU SEAN; RABINOWITZ JOSHUA D; SHENK THOMAS
权利人:LIU SEAN; RABINOWITZ JOSHUA D; SHENK THOMAS; UNIV PRINCETON
摘要:A method of treating or preventing a viral infection in a mammal by administering a compound or pharmaceutically acceptable derivative thereof that inhibits a phosphatidic acid synthesis enzyme.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Overbeek BP, Schellekens JF, Lippe W, Dekker BA, Verhoef J. Carumonam enhances reactivity of Escherichia coli with mono- and polyclonal antisera to rough Escherichia coli J5. J Clin Microbiol. 1987 Jun;25(6):1009-13.
2: Hirasawa M, Takada K. Susceptibility of Streptococcus mutans and Streptococcus sobrinus to cell wall inhibitors and development of a novel selective medium for S. sobrinus. Caries Res. 2002 May-Jun;36(3):155-60.
合成参考文献
参考文献:10.1007/s101560200022
摘要:Kumazawa J, Yagisawa M. The history of antibiotics: the Japanese story. J Infect Chemother. 2002 Jun;8(2):125–33. doi: 10.1007/s101560200022.
摘要:Kumamoto Y, Tsukamoto T, Matsukawa M, Kunishima Y, Hirose T, Shigeta S, Yamaguti O, Ishibashi K, Suzutani T, Yoshida H, Imafuku Y, Murai M, Watanabe K, Kobayashi Y, Uchida H, Matsuda S, Sato S, Fujime M, Fujita K, Igari J, Oguri T, Yamaguchi K, Furuya N, Deguchi T, Ishihara S, Ooe H, Oka T, Kitamura M, Fukuhara Y, Kamidono S, Arakawa S, Kumon H, Monden K, Matsumoto T, Muratani T, Naito S, Egashira T, Konishi T, Kohno S, Hirakata Y, Kondo A, Matsuda J, Nakano M. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution]. Jpn J Antibiot. 2006 Jun;59(3):177–200.
摘要:Kanellakopoulou K, Manta M, Tsagaraki C, Giamarellou H. In vitro and in vivo experience with carumonam: a preliminary report. J Chemother. 1989 Jul;1(4 Suppl):125.
📝 需求与反馈
尽可能描述清楚需求与问题信息
